RE: Shareholder returns28 Mar 2023 17:13
Looking forward to see the progress, especially the cost base reduction.
"However, we are encouraged by recent NIPT contract wins, the completion of our DPYD FDA pre-submission and the growing body of clinical evidence to support Ranger® Technology application in different fields. All indicators show that our core markets are growing.
"In addition, we have a key focus on reducing cost base with operational efficiencies at our new single site UK headquarters including improvements to our manufacturing process."